EYEGENE Inc.

EyeGene R&D Center was officially authorized in May 2001 and has been dedicated to developing innovative biopharmaceuticals, vaccines, and diagnostic system for the treatment and prevention of age-related diseases.
On November 1, 2016, we relocated and expanded the R&D Center, and have added pilot scale production facilities. EyeGene will continue to strive to build competence as a specialist in the research and development of innovative biopharmaceuticals and vaccines. In particular, our R&D Center’s core value and competitiveness stems from the recruitment and nurture of outstanding research talent in biopharmaceutical research and development that is extremely technology-intensive. As such, our R&D center strives to attract outstanding domestic research talent through providing ample educational opportunities in order for them to transform EyeGene into a leading global research based biotechnology company

R & D